HLA-DRB1*1501 and VDR polymorphisms and survival of Mycobacterium tuberculosis in human macrophages exposed to inhalable microparticles.

abstract：:High-throughput data collection using gene microarrays has great potential as a method for addressing the pharmacogenomics of complex biological systems. Similarly, mechanism-based pharmacokinetic/pharmacodynamic modeling provides a tool for formulating quantitative testable hypotheses concerning the responses of comp...

journal_title：Pharmacogenomics

authors： Almon RR,DuBois DC,Piel WH,Jusko WJ

更新日期：2004-07-01 00:00:00

abstract：AIM:To determine the availability of pharmacogenetic and pharmacogenomic information for healthcare professionals in France during 2009 for anticancer drugs. MATERIALS & METHODS:We searched in the informatic version of the VIDAL dictionary which is currently used by healthcare professionals in France. We then compared...

journal_title：Pharmacogenomics

authors： Albertini L,Siest G,Jeannesson E,Visvikis-Siest S

更新日期：2011-05-01 00:00:00

abstract：:The second Annual Meeting of the UK Pharmacogenetics and Stratified Medicine Network was held on 28 September 2011 at The Wellcome Trust Conference Centre on the Wellcome Trust Genome Campus at Hinxton, Cambridge, UK. The meeting preceded the annual Pharmacogenomics and Personalized Medicine conference, which was held...

journal_title：Pharmacogenomics

authors： Hall I

更新日期：2012-01-01 00:00:00

abstract：AIM:Hemoglobinopathies exhibit a remarkable phenotypic diversity that restricts any safe association between molecular pathology and clinical outcomes. PATIENTS & METHODS:Herein, we explored the role of genes involved in the nitric oxide biosynthesis and signaling pathway, implicated in the increase of fetal hemoglobi...

journal_title：Pharmacogenomics

authors： Chalikiopoulou C,Tavianatou AG,Sgourou A,Kourakli A,Kelepouri D,Chrysanthakopoulou M,Kanelaki VK,Mourdoukoutas E,Siamoglou S,John A,Symeonidis A,Ali BR,Katsila T,Papachatzopoulou A,Patrinos GP

更新日期：2016-03-01 00:00:00

abstract：:Interindividual variability in drug response and the emergence of adverse drug effects are the main causes of treatment failure in cancer therapy. Functional membrane drug transporters play important roles in altering pharmacokinetic profile, resistance to treatment, toxicity and patient survival. Pharmacogenetic stud...

journal_title：Pharmacogenomics

authors： Jabir RS,Naidu R,Annuar MA,Ho GF,Munisamy M,Stanslas J

更新日期：2012-12-01 00:00:00

abstract：:In this report, we review the importance of pharmacovigilance in detecting postmarketing adverse drug events and the potential for developing pharmacogenovigilance programs by integrating pharmacogenomics with pharmacovigilance. We propose to start developing such a program in primary healthcare systems that use basic...

journal_title：Pharmacogenomics

authors： Awada Z,Zgheib NK

更新日期：2014-04-01 00:00:00

abstract：:Evaluating the prospects for 'personalized healthcare' has become topical at the 10-year anniversary of the first results from the Human Genome Project. The coincidence of this milestone with a period of global financial difficulty is unfortunate, but industry has signaled its willingness to invest in this new medical...

journal_title：Pharmacogenomics

authors： Creeden J

更新日期：2012-11-01 00:00:00

abstract：:Founded as a spin-off from the University of Vienna in 1999, VBC-GENOMICS Bioscience Research GmbH (LLC) has rapidly gained a strong position within the Austrian biotech scene, based on its success as a service provider in oligonucleotide synthesis and custom sequencing. In research, the company has focused on the dev...

journal_title：Pharmacogenomics

authors： Schmidt WM

更新日期：2004-06-01 00:00:00

abstract：:Aim: To determine if selected serotonergic and noradrenergic gene variants are associated with heroin addiction. Subjects & methods: A total of 126 variants in 19 genes in subjects with Dutch European ancestry from The Netherlands. Subjects included 281 opioid-dependent volunteers in methadone maintenance or heroin-as...

journal_title：Pharmacogenomics

authors： Randesi M,van den Brink W,Levran O,Blanken P,van Ree JM,Ott J,Kreek MJ

更新日期：2019-04-01 00:00:00

abstract：AIM:Approximately a third of newly diagnosed epilepsy patients do not respond to antiepileptic drugs (AEDs). Evidence suggests that low penetrance variants in the genes of drug targets such as voltage-gated sodium channels may be involved in drug responsiveness. To examine this hypothesis, we compared data from two epi...

journal_title：Pharmacogenomics

authors： Haerian BS,Baum L,Kwan P,Tan HJ,Raymond AA,Mohamed Z

更新日期：2013-07-01 00:00:00

abstract：:The aim of this work was to determine the VKORC1 haplotype profile in healthy Hungarian and Roma population samples, and to compare our data with other selected populations. Using haplotype tagging SNPs (G-1639A, G9041A and C6009T), we characterized Hungarian (n = 510) and Roma (n = 451) population samples with regard...

journal_title：Pharmacogenomics

authors： Sipeky C,Csongei V,Jaromi L,Safrany E,Polgar N,Lakner L,Szabo M,Takacs I,Melegh B

更新日期：2009-06-01 00:00:00

abstract：:Skeletal muscle toxicity is the primary adverse effect of statins. In this review, we summarize current knowledge regarding the genetic and nongenetic determinants of risk for statin induced myopathy. Many genetic factors were initially identified through candidate gene association studies limited to pharmacokinetic (...

journal_title：Pharmacogenomics

authors： Feng Q,Wilke RA,Baye TM

更新日期：2012-04-01 00:00:00

abstract：:High-throughput genotyping approaches are being developed to meet the demands of pharmacogenomnics, where numerous individuals are studied with thousands of single nucleotide polymorphism (SNP) markers. All non-gel-based genotyping approaches achieve allelic discrimination by one of four mechanisms: allele-specific hy...

journal_title：Pharmacogenomics

authors： Kwok PY

更新日期：2000-02-01 00:00:00

abstract：:The NIH initiated the PharmGKB in April 2000. The primary mission was to create a repository of primary data, tools to track associations between genes and drugs, and to catalog the location and frequency of genetic variations known to impact drug response. Over the past 10 years, new technologies have shifted researc...

journal_title：Pharmacogenomics

authors： Thorn CF,Klein TE,Altman RB

更新日期：2010-04-01 00:00:00

abstract：:This narrative review describes implementation, current status and perspectives of a pharmacogenomic (PGx) program at the Brazilian National Cancer Institute (INCA), targeting the cancer chemotherapeutic drugs - fluoropyrimidines, irinotecan and thiopurines. This initiative, designed as a research project, was support...

journal_title：Pharmacogenomics

authors： Suarez-Kurtz G,Kovaleski G,Elias AB,Motta V,Wolch K,Emerenciano M,Mansur MB,Palladino AM,Accioly MT,Ferreira M,Gonçalves AA,de Melo AC

更新日期：2020-06-01 00:00:00

abstract：UNLABELLED:Glutathione S-transferases (GSTs) participate in the detoxification of chemotherapeutic agents. Genetic polymorphisms in GST genes (GSTP1 Ile105Val, copy-number variants of GSTM1 and GSTT1) that lead to diminished enzyme activity have been associated with increased chemotherapeutic treatment benefit in color...

journal_title：Pharmacogenomics

authors： Funke S,Timofeeva M,Risch A,Hoffmeister M,Stegmaier C,Seiler CM,Brenner H,Chang-Claude J

更新日期：2010-01-01 00:00:00

abstract：:Abacavir is an effective antiretroviral drug used to treat HIV-1 infection. Approximately 5% of patients treated with abacavir develop a hypersensitivity reaction that requires discontinuation of the drug. In an initial pharmacogenetic study conducted in a predominantly White male population, multiple markers in the h...

journal_title：Pharmacogenomics

authors： Hughes AR,Mosteller M,Bansal AT,Davies K,Haneline SA,Lai EH,Nangle K,Scott T,Spreen WR,Warren LL,Roses AD,CNA30027 Study Team.,CNA30032 Study Team.

更新日期：2004-03-01 00:00:00

abstract：:This review will summarize the role of pharmacogenetics in the natural history of hepatitis C, particularly in patients with HIV/HCV and will take the perspective of pharmacogenetics and its influence on the response to antiviral therapy and the susceptibility to develop adverse effects. This review will also devote a...

journal_title：Pharmacogenomics

authors： Frias M,Rivero-Juárez A,López-López P,Rivero A

更新日期：2018-08-01 00:00:00

abstract：:Cost-effectiveness analysis is a widely used tool to assess the value of healthcare interventions. Our objective was to conduct a systematic review of the literature on the cost effectiveness of pharmacogenomic interventions. We found 11 studies that met our inclusion criteria. The most commonly examined disease was d...

journal_title：Pharmacogenomics

authors： Phillips KA,Van Bebber SL

更新日期：2004-12-01 00:00:00

abstract：AIM:A population pharmacokinetic (PPK) analysis was conducted to describe the influence of GSTA1 polymorphisms on intravenous busulfan in adults undergoing allogeneic hematopoietic stem cell transplantation. PATIENTS & METHODS:A PPK model was developed from 36 patients by a one-compartment model with first-order elimi...

journal_title：Pharmacogenomics

authors： Choi B,Kim MG,Han N,Kim T,Ji E,Park S,Kim IW,Oh JM

更新日期：2015-01-01 00:00:00

abstract：AIMS:The importance of polymorphisms in the dihydropyrimidine dehydrogenase gene (DPYD) for the prediction of severe toxicity in 5-fluorouracil (5-FU)-based chemotherapy is still unclear. This study aims to assess the predictive value of DPYD variation with respect to previously described DPYD variants for 5-FU toxicit...

journal_title：Pharmacogenomics

authors： Amstutz U,Farese S,Aebi S,Largiadèr CR

更新日期：2009-06-01 00:00:00

abstract：:PON1 is a key component of high-density lipoproteins (HDLs) and is at least partially responsible for HDL's antioxidant/atheroprotective properties. PON1 is also associated with numerous human diseases, including cardiovascular disease, Parkinson's disease and cancer. In addition, PON1 metabolizes a broad variety of s...

journal_title：Pharmacogenomics

authors： Kim DS,Marsillach J,Furlong CE,Jarvik GP

更新日期：2013-09-01 00:00:00

abstract：:Pharmacogenomics (PGx) implementation in clinical practice is steadily increasing. PGx uses genetic information to personalize medication use, which increases medication efficacy and decreases side effects. The availability of clinical PGx guidelines is essential for its implementation in clinical settings. Currently,...

journal_title：Pharmacogenomics

authors： Nagy M,Attya M,Patrinos GP

更新日期：2020-11-01 00:00:00

abstract：AIM:We investigated 16 polymorphisms from three genes, dopamine receptor D2 (DRD2), catechol-O-methyl transferase (COMT) and brain derived neurotrophic factor (BDNF), which are involved in the dopaminergic pathways, and have been reported to be associated with susceptibility to schizophrenia and response to antipsychot...

journal_title：Pharmacogenomics

authors： Gupta M,Chauhan C,Bhatnagar P,Gupta S,Grover S,Singh PK,Purushottam M,Mukherjee O,Jain S,Brahmachari SK,Kukreti R

更新日期：2009-02-01 00:00:00

abstract：:HER2 upregulation is related with poor outcome in many tumor types. Whereas anti-HER2 treatment is the standard approach as adjuvant therapy in HER2-overexpressing breast cancer, the frequent relapses reinforce the need for alternative treatments. Here we used next-generation sequencing (NGS) to evaluate miRNAs and ci...

journal_title：Pharmacogenomics

authors： Galli de Amorim M,Branco G,Valieris R,Tarcitano E,Tojal da Silva I,Ferreira de Araújo L,Noronha Nunes D,Dias-Neto E

更新日期：2019-05-01 00:00:00

abstract：:In the growing field of genomics, the utility of returning certain research results to participants has become a highly debated issue. Existing guidelines are not explicit as to the kind of genomic information that should be returned to research participants. Moreover, very few current recommendations and articles in ...

journal_title：Pharmacogenomics

authors： Korol S,Hurlimann T,Godard B,de Denus S

更新日期：2013-04-01 00:00:00

abstract：:The narrow therapeutic range and wide interpatient variability in dose requirement make anticoagulation response to coumarin derivatives unpredictable. As a result, patients require frequent monitoring to avert adverse effects and maintain therapeutic efficacy. Polymorphisms in VKORC1 and CYP2C9 jointly account for ab...

journal_title：Pharmacogenomics

authors： van Schie RM,Wadelius MI,Kamali F,Daly AK,Manolopoulos VG,de Boer A,Barallon R,Verhoef TI,Kirchheiner J,Haschke-Becher E,Briz M,Rosendaal FR,Redekop WK,Pirmohamed M,Maitland van der Zee AH

更新日期：2009-10-01 00:00:00

abstract：AIM:To determine the clinical and genetic predictors of the dipeptidyl peptidase-4 (DPP-4) inhibitor treatment response in Type 2 diabetes mellitus (T2DM) patients. PATIENTS & METHODS:DPP4, WFS1 and KCNJ11 gene polymorphisms were genotyped in a cohort study of 662 T2DM patients treated with DPP-4 inhibitors sitaglipti...

journal_title：Pharmacogenomics

authors： Jamaluddin JL,Huri HZ,Vethakkan SR

更新日期：2016-06-01 00:00:00

abstract：BACKGROUND:Prednisolone is a potent anti-inflammatory glucocorticoid (GC) but chronic use is hampered by metabolic side effects. Little is known about the long-term effects of GCs on gene-expression in vivo during inflammation. AIM:Identify gene signatures underlying prednisolone-induced metabolic side effects in a co...

journal_title：Pharmacogenomics

authors： Ellero-Simatos S,Fleuren WW,Bauerschmidt S,Dokter WH,Toonen EJ

更新日期：2014-04-01 00:00:00

abstract：:Assessing the distinct prevalence or absence of genetic variants associated with differential response to the anticoagulant medication of warfarin in different population groups is actively pursued by pharmacogenomics community. Populations from Arabian Peninsula are underrepresented in such studies. By way of examini...

journal_title：Pharmacogenomics

authors： John SE,Antony D,Eaaswarkhanth M,Hebbar P,Alkayal F,Tuomilehto J,Alsmadi O,Thanaraj TA

更新日期：2017-06-01 00:00:00